7 citations
,
March 2022 in “Molecules” 5-Bromo-3,4-dihydroxybenzaldehyde could potentially help hair growth by activating certain cell pathways and inhibiting others.
8 citations
,
August 1987 in “The Journal of Dermatology” BKN-1 antibody targets specific keratin in basal cell epithelioma and normal skin basal cells.
111 citations
,
April 2000 in “British journal of dermatology/British journal of dermatology, Supplement” Thyroid hormone receptor β1 is found in human hair follicles and helps them survive.
May 2023 in “The Journal of Immunology” BST2 is a key marker for hair loss disease alopecia areata.
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
November 1997 in “Open Archive (Karolinska Institutet)” PTCH gene mutations contribute to basal cell carcinoma development.
1 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
26 citations
,
August 2019 in “Stem Cell Research & Therapy” PBX1 helps hair stem cells grow and change by turning on certain cell signals and preventing cell death, which may be useful for hair regrowth treatments.
10 citations
,
October 2014 in “Plastic & Reconstructive Surgery Global Open” Botulinum toxin type A injections improved hair growth and scalp health in a woman with radiation-induced hair loss.
5 citations
,
October 2021 in “American Journal of Medical Genetics Part A” A new genetic variant causes BRESHECK syndrome by disrupting cell growth and stress response.
19 citations
,
April 2014 in “Expert opinion on emerging drugs” New treatments for a type of skin cancer show promise but have side effects and may work better with other therapies.
January 2026 in “Dermatologic Therapy” Photobiomodulation therapy effectively promotes hair regrowth and improves quality of life in alopecia areata without side effects.
3 citations
,
January 2022 in “Neurotoxicity Research” Botulinum toxin may help reduce stress-related hair loss.
143 citations
,
May 2002 in “PubMed” LGD1069 effectively prevents breast tumors in mice without toxicity.
Baricitinib is more effective than methotrexate for severe alopecia areata.
October 2024 in “Endocrinology Insights” The Bethesda system is effective for identifying thyroid cancer but has low sensitivity.
Introducing the OTC gene improved symptoms in mice with OTC deficiency.
November 2023 in “JEADV Clinical Practice” Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
1 citations
,
October 2022 in “Molecular therapy” The FDA approved the first gene therapy for a blood disorder after overcoming early challenges and demonstrating patient benefits.
September 2024 in “Journal of Microbiology and Biotechnology” The tonic boosts hair growth and fights dandruff using natural electric energy.
November 2016 in “Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)” The VMH AMPK-SNS-BAT axis may help treat cachexia and obesity.
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
121 citations
,
December 2001 in “American Journal of Dermatopathology” TB and BCC tumors show similar follicular differentiation patterns.
July 2023 in “Journal of Microbiology and Biotechnology” Terminalia bellirica extract may help promote hair growth and prevent hair loss caused by testosterone.
January 2025 in “International Journal of Trichology” Trichotillomania can occur in unusual patterns and sites, highlighting the need for awareness and treatment options.
BCG injection helps reduce long COVID symptoms and affects hair loss differently in men and women.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
May 2023 in “Indian Journal of Dermatology” BCG site reactions after COVID-19 mRNA vaccination are mild, temporary, and likely under-reported.